Could Cesarean Delivery Help Prevent Mother-to-Child Transmission of Human T-Lymphotropic Virus Type 1?

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
HAZIOT, Michel E.
SMID, Jerusa
MARCUSSO, Rosa Maria do N.
OLIVEIRA, Augusto. C. P. de
Citação
JOURNAL OF INFECTIOUS DISEASES, v.228, n.12, p.1766-1775, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Mother-to-child transmission (MTCT) of human T-lymphotropic virus type 1 (HTLV-1) is an important route of transmission that can cause lifelong infection. There is high morbidity and mortality due to adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy (HAM), and other inflammatory disorders. These conditions develop in nearly 10% of people with HTLV-1 infection, with a higher risk if infection occurs early in life. Identification of risk factors can inform targeted measures to reduce HTLV-1 MTCT. This study aimed to investigate the potential of cesarean delivery to prevent HTLV-1 MTCT. Methods. We performed a review of the cases of women and their offspring under regular follow-up at the HTLV-1 outpatient clinic at the Institute of Infectious Diseases Emilio Ribas. Results. A total of 177 HTLV-1-infected women and 369 adult offspring were investigated. Overall, 15% of the children were positive for HTLV-1 and 85% were negative. Regarding vertical transmission, we found that a breastfeeding duration of >6 months was associated with MTCT. Moreover, maternal proviral load was not associated with transmission, but high educational level and cesarean delivery were identified as protective factors. Conclusions. HTLV-1 MTCT was associated with mother's age at delivery of >25 years, low educational level, prolonged breastfeeding, and vaginal delivery.
Palavras-chave
HTLV-1, breastfeeding, cesarean delivery, mother-to-child transmission, risk factors
URI
https://observatorio.fm.usp.br/handle/OPI/58858
Referências
  1. Ydy RRA, 2009, REV SOC BRAS MED TRO, V42, P28, DOI 10.1590/S0037-86822009000100007
  2. Bandeira LM, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009066
  3. Biggar RJ, 2006, J INFECT DIS, V193, P277, DOI 10.1086/498910
  4. Bohiltea RE, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9514
  5. Carles G, 2004, J Gynecol Obstet Biol Reprod (Paris), V33, P14
  6. Carneiro-Proietti ABF, 2014, J PEDIATR INFECT DIS, V3, pS24, DOI 10.1093/jpids/piu070
  7. Cooper CMJ, 2010, W INDIAN MED J, V59, P35
  8. Garcia IFD, 2021, CAD SAUDE PUBLICA, V37, DOI [10.1590/0102-311X00303420, 10.1590/0102-311x00303420]
  9. Dal Fabbrol MMFJ, 2008, REV SOC BRAS MED TRO, V41, P148, DOI 10.1590/S0037-86822008000200003
  10. Friedrich L, 2016, Bol Cient Pediatr, V5, P81
  11. Gessain A, 2012, REV NEUROL-FRANCE, V168, P257, DOI 10.1016/j.neurol.2011.12.006
  12. Mello MAG, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-28
  13. Haziot ME, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006967
  14. Hino S, 1996, J ACQ IMMUN DEF SYND, V13, pS199, DOI 10.1097/00042560-199600001-00030
  15. Hino S, 2011, P JPN ACAD B-PHYS, V87, P152, DOI 10.2183/pjab.87.152
  16. Itabashi K, 2021, CANCERS, V13, DOI 10.3390/cancers13164100
  17. Itabashi K, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00595
  18. Iwanaga M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01124
  19. Izumo Shuji, 1997, Leukemia (Basingstoke), V11, P82
  20. Jia N, 2018, ASIA PAC J CLIN NUTR, V27, P1294, DOI 10.6133/apjcn.201811_27(6).0017
  21. Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x
  22. Kashiwagi K, 2004, AM J TROP MED HYG, V70, P158, DOI 10.4269/ajtmh.2004.70.158
  23. KATAMINE S, 1994, LANCET, V343, P1326, DOI 10.1016/S0140-6736(94)92469-4
  24. KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x
  25. Kitaw TM, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03706-8
  26. LeVasseur R J, 1998, J Hum Virol, V1, P214
  27. Li HC, 2004, J INFECT DIS, V190, P1275, DOI 10.1086/423941
  28. Filho ACM, 2010, REV BRAS GINECOL OBS, V32, P176, DOI 10.1590/S0100-72032010000400005
  29. Martin F, 2018, LANCET, V391, P1893, DOI 10.1016/S0140-6736(18)30974-7
  30. de Lima LHM, 2009, CAD SAUDE PUBLICA, V25, P668, DOI 10.1590/S0102-311X2009000300021
  31. Montanheito PA, 2005, BRAZ J MED BIOL RES, V38, P1643, DOI 10.1590/S0100-879X2005001100011
  32. Moriuchi H, 2013, PEDIATR INFECT DIS J, V32, P175, DOI 10.1097/INF.0b013e31827efc39
  33. Nascidos vivos, Tabnet. 3.0: Nascidos vivos-Brasil
  34. Paiva AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25939-y
  35. Rosadas C, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009717
  36. Rosadas C, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006913
  37. Satake M, 2023, J MED VIROL, V95, DOI 10.1002/jmv.28606
  38. Sequeira CG, 2012, REV SOC BRAS MED TRO, V45, P453, DOI 10.1590/S0037-86822012005000007
  39. Barmpas DBS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007404
  40. Takezaki Toshiro, 1997, Leukemia (Basingstoke), V11, P60
  41. Tezuka K, 2020, J CLIN INVEST, V130, P6171, DOI 10.1172/JCI135525
  42. Toth FD, 1995, AIDS RES HUM RETROV, V11, P1495, DOI 10.1089/aid.1995.11.1495
  43. TSUJI Y, 1990, PEDIATRICS, V86, P11
  44. Ureta-Vidal A, 1999, INT J CANCER, V82, P832, DOI 10.1002/(SICI)1097-0215(19990909)82:6<832::AID-IJC11>3.0.CO;2-P
  45. van Tienen C, 2012, AIDS RES HUM RETROV, V28, P584, DOI [10.1089/aid.2011.0219, 10.1089/AID.2011.0219]
  46. World Health Organization, 2021, New WHO report on human T-lymphotropic virus type 1 highlights strategies for its prevention and control
  47. Zihlmann KF, 2017, ACTA PAUL ENFERM, V30, P80, DOI 10.1590/1982-0194201700012
  48. Zihlmann KF, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001705

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT